Am J Transplant, Volume 18, Suppl 3 Archives - Page 158 of 211 - ATC Abstracts

2018 American Transplant Congress
Treatment and Outcomes of Orthotopic Liver Transplant Patients Secondary to Hepatitis C Virus: A Single Center Experience
T. Chen,¹ M. Moaddab,¹ B. Pierce,¹ R. Ghobrial.²
¹Department of Pharmacy, Houston Methodist Hospital, Houston, TX; ²Department of Surgery, Houston Methodist Hospital, Houston, TX.
Background: Treatment of acute cellular rejection (ACR) in patients with orthotopic liver transplantation (OLT) secondary to hepatitis C virus (HCV) remains a major challenge due…
2018 American Transplant Congress
Prostate Cancer Characteristics in Men on Immunosuppressive Medications
M. Eltemamy, A. Elshafei, A. Salah, Y. Nyame, H. Arora, A. Wee, V. Krishnamurthi, S. Jones.
Cleveland Clinic, Cleveland.
INTRODUCTION: To assess the prevalence of prostate cancer (PCa) in men receiving immunosuppressive medications undergoing transrectal ultrasound guided (TRUS) prostate biopsy.METHODS: A total of 468…
2018 American Transplant Congress
Hypothermic Oxygenated Machine Perfusion in Liver and Kidney Transplantation of Extended Criteria Donors: A Phase-1 of Clinical Trial
M. Ravaioli,¹ V. De Pace,¹ M. Cescon,¹ M. Del Gaudio,¹ V. R. Bertuzzo,¹ A. Siniscalchi,¹ A. D'Errico,² G. Comai,² G. La Manna,² A. D. Pinna.¹
¹General Surgery and Transplantation, University of Bologna Sant'Orsola - Malpighi Hospital, Bologna, Emilia Romagna, Italy; ²Experimental Diagnostic and Specialty Medicine, University of Bologna Sant'Orsola- Malpighi Hospital, Bologna, Emilia Romagna, Italy.
In the field of liver (LT) and kidney transplantation (KT), extended criteria donors (ECD) offer an additional organ source that is more vulnerable for early…
2018 American Transplant Congress
Is Kidney Transplantation Safe in Patients over 71 Years Old?
G. Andani, P. Tulissi, M. Gropuzzo, S. Crestani, C. Vallone, U. Baccarani, D. Montanaro, A. Risaliti.
Department of Kidney & Liver Transplantation, ASUIUD, Udine, Italy.
Introduction: Kidney transplantation in elderly patients is superior over dialysis as therapy for end stage renal disease (ESRD). We analyzed different parameters to evaluate patient…
2018 American Transplant Congress
Early versus Late Cytomegalovirus Prophylaxis after Kidney Transplant
M. Harris, J. Byrns, J. Gommer, M. Laub, M. Ellis.
Duke University Hospital, Durham, NC.
Background: Prophylaxis against cytomegalovirus (CMV) is recommended in high-risk patients (CMV D+/R-) and those who are CMVR+ and getting T-cell depletional therapy. It is unclear…
2018 American Transplant Congress
Early Blockade of Toll-Like Receptor 4 Reduces Ischemia-Reperfusion Injury and Improves Islet Transplantation Outcomes
C. Chang,¹ M. Lawrence,² R. Kane,¹ B. Naziruddin.³
¹Institute of Biomedical Studies, Baylor University, Waco; ²Baylor Scott & White Research Institute, Dallas; ³Baylor Simmons Transplant Institute, Dallas.
Purpose: Inflammatory damage to islets during isolation is a major hurdle for success in transplantation. We investigated the safety and therapeutic potential of pharmacological blockade…
2018 American Transplant Congress
Is KDPI Valid for Hepatitis C Aviremic Kidneys?
L. Sibulesky,¹ C. Kling,¹ C. Blosser,² C. Johnson,² A. Limaye,² R. Bakthavatsalam,¹ N. Leca,² J. Perkins.¹
¹Surgery, University of Washington Medical Center, Seattle, WA; ²Medicine, University of Washington Medical Center, Seattle, WA.
KDRI is an estimate of post-transplant kidney graft failure. It is based on ten donor factors that independently affect transplant outcomes, including HCV status from…
2018 American Transplant Congress
The Impact of Rituximab Dose on Hepatitis B Virus Reactivation in HBsAg-Negative/anti-HBc-Positive Kidney Transplant Recipients
J. Lee,¹ J. Park,² Y. Jung,¹ D. Kim,¹ J. Lee,¹ S. Song,³ J. Lee,⁴ J. Lee,¹ B. Kim,⁵ M. Kim,¹ S. Kim,¹ Y. Kim,¹ K. Huh.¹
¹Surgery, Yonsei University College of Medicine, Seoul, Korea; ²Internal Medicine (Gastroenterology), Yonsei University College of Medicine, Seoul, Korea; ³Surgery, Ewha Womans University, School of Medicine, Seoul, Korea; ⁴Surgery, CHA Bundang Medical Center, CHA University, Seongnam, Korea; ⁵Internal Medicine (Nephrology), Yonsei University College of Medicine, Seoul, Korea.
Background: Hepatitis B virus (HBV) reactivation is well-recognized complication of rituximab. Although use of rituximab for sensitized patients continues to increase in kidney transplantation, the…
2018 American Transplant Congress
mTOR Inhibition with Everolimus in De Novo Living Donor Liver Transplantation – 24-Months Results from the H2307 Pivotal Trial
L. Jeng,¹ S. Lee,¹ A. Soin,¹ S. Uemoto,¹ D. Maluf,¹ J. Emond,¹ M. Meier,² J. Kochuparampil,² C. Sips,² S. Kaneko,³ G. Levy.¹
¹H2307 Study Group, Taichung, Taiwan; ²Novartis Pharma AG, Basel, Switzerland; ³Novartis Pharma KK, Tokyo, Japan.
Purpose: Everolimus (EVR) with reduced-dose tacrolimus (rTAC) has been shown to be efficacious in preventing graft rejection and improving renal function in deceased-donor liver transplant…
2018 American Transplant Congress
EVLP on Donor Lungs: National Trends and Outcomes
R. Lehman,¹ R. Carrico,¹ K. Uccellini,¹ K. Chan,² T. Whelan.³
¹United Network for Organ Sharing, Richmond, VA; ²Univ of Michigan, Ann Arbor, MI; ³Medical Univ of South Carolina, Charleston, SC.
Purpose: The OPTN/UNOS added fields to the deceased donor registration form on 3/31/2015 to capture the intent to utilize ex vivo lung perfusion (EVLP) on…